浙江九洲药业股份有限公司关于全资子公司参与投资嘉兴隆峰创业投资合伙企业（有限合伙）的公告

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is investing in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) through its wholly-owned subsidiary, with a total investment amount of RMB 77 million, of which Jiuzhou's contribution is RMB 10 million, accounting for 12.987% of the total [2][4]. Investment Overview - The investment is aimed at sectors related to new drug development and medical device research, focusing on high-quality emerging medical enterprises, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research [2][12]. - The total subscribed capital of the partnership is RMB 77 million, which includes Jiuzhou's investment [4][12]. Partnership Agreement Details - The partnership agreement involves multiple partners, including Shihezi Longtai Equity Investment Management Partnership (Limited Partnership) and others, with Jiuzhou's subsidiary as a limited partner [4][5]. - The partnership has a duration of 6 years, with an investment period of 1.5 years and an exit period of 4.5 years [14]. - The management fee is set at 2% per year based on the total paid-in capital, with no management fee during the extension period [17]. Financial Impact and Strategic Alignment - This investment aligns with the company's overall development strategy and aims to leverage the expertise of professional investment management institutions to expand investment channels and generate returns [21]. - The investment is not expected to have a significant impact on the company's financial and operational status, complying with relevant laws and regulations [21].